Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497320 | 1.00 | FAAH (0.42) | FAAHTRPV1PPARA | |
| SCHEMBL1532449 | 0.83 | TSHR (0.50) | — | |
| SCHEMBL10495800 | 0.83 | TSHR (0.50) | — | |
| SCHEMBL1668578 | 0.83 | TSHR (0.50) | — | |
| SCHEMBL987948 | 0.83 | TSHR (0.50) | — | |
| SCHEMBL6055711 | 0.82 | TSHR (0.46) | — | |
| Hydrochloric Acid SCHEMBL28147327 | 0.81 | TSHR (0.48) | — | |
| SCHEMBL9236626 | 0.75 | FAAH (0.45) | FAAHTRPV1 | |
| SCHEMBL34463867 | 0.73 | FAAH (0.48) | FAAHTRPV1PPARA | |
| SCHEMBL5974308 | 0.73 | FAAH (0.48) | FAAHTRPV1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030445-B2 | Glycopeptide derivative | THERAVANCE, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-7723470-B2 | Glycopeptide derivatives and pharmaceutical compositions containing the same | THERAVANCE, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090215982-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CUMBERLAND PHARMACEUTICALS INC. | 2009-08-27 | — | — | US | disclosed |
| US-20080103292-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | CUMBERLAND PHARMACEUTICALS INC. | 2008-05-01 | — | — | US | disclosed |
| US-7351791-B2 | Intermediate for preparing glycopeptide derivatives | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060241024-A1 | Intermediate for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2006-10-26 | — | — | US | disclosed |
| US-7101964-B2 | Intermediate for preparing glycopeptide derivatives | THERAVANCE, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-6962970-B2 | Glycopeptide derivatives and pharmaceutical compositions containing the same | THERAVANCE, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050239690-A1 | Intermediate for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2005-10-27 | — | — | US | disclosed |
| US-6949681-B2 | Intermediate for preparing glycopeptide derivatives | THERAVANCE, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040204346-A1 | Intermediate for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1140993-B1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | THERAVANCE INC (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030060598-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | CUMBERLAND PHARMACEUTICALS INC. | 2003-03-27 | — | — | US | disclosed |
| US-20030008812-A1 | Glycopeptide derivatives | THERAVANCE, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6455669-B1 | GLYCOPROTEIN FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS | THERAVANCE, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6444786-B1 | BACTERICIDES | ADVANCED MEDICINE, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6392012-B1 | COMPOUND FOR USE IN TREATMENT AND PREVENTION OF BACTERIAL INFECTION | ADVANCED MEDICINE, INC. | 2002-05-21 | — | — | US | disclosed |
| EP-1140993-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Advanced Medicine, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039156-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADVANCED MEDICINE, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103292-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | GYPA, RDX, VIP | FAAH 4869/4885TRPV1 3847/4885PPARA 3590/4885 |
| US-20050239690-A1 | Intermediate for preparing glycopeptide derivatives | GYPA, MGAT3, RDX | FAAH 4872/4885TRPV1 4425/4885PPARA 4357/4885 |
| US-20090215982-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GYPA, RDX, VIP | FAAH 4869/4885TRPV1 3847/4885PPARA 3590/4885 |
| US-20040204346-A1 | Intermediate for preparing glycopeptide derivatives | NGLY1, FUT6, ST3GAL3 | FAAH 4194/4885TRPV1 4068/4885PPARA 4038/4885 |
| US-20030008812-A1 | Glycopeptide derivatives | MGAT3, GYPA, GIPR | FAAH 4848/4885TRPV1 4601/4885PPARA 3832/4885 |
| US-20060241024-A1 | Intermediate for preparing glycopeptide derivatives | B3GAT3, ST3GAL3, OGT | FAAH 4558/4885TRPV1 4065/4885PPARA 4324/4885 |
| US-20030060598-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | GYPA, RDX, MGAT3 | FAAH 4706/4885TRPV1 3844/4885PPARA 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.